Randomized trial evaluated a silodosin buccal film's effectiveness in enhancing drug release and stability in treatment of hyperplasia, implying improved patient compliance.
Objective: The objective of this research work was to formulate and evaluate buccal film containing Silodosin by enhancement of Permeability by preparing inclusion complex of Silodosin with ꞵ-CD and to increase patient compliance which is useful in the treatment of Hyperplasia. Materials and Methods: In this research, the method used to prepare buccal films was solvent casting. ꞵ-CD inclusion complex with silodosin in 1:1 ratio to increase permeability of drug. 32 Full Factorial design was used for optimization by selecting two independent factors –concentration of film forming agent (HPMC E5)-X I and concentration of plasticizer (Propylene glycol)-X II and their effect on Disintegration time- (R I), and % drug release- (R II). Optimization of factorial batches was done using Design Expert 13 software. Result: Best results were obtained in Batch F1 in which HPMC E5 was 150mg and Propylene glycol was 1ml with 31.4 seconds of disintegration time and 99.1 % cumulative drug release at 15 minutes. Check point batch shows 34.74 seconds of disintegration time 97.09 % cumulative drug release. A 1 month accelerated Short term stability study was done on prepared films and it is stable for 1 month. Conclusion: Buccal film containing Silodosin were formulated using HPMC E5 as a film forming and Propylene glycol as a plasticizer by solvent casting method. Hence, from the results it was concluded that faster disintegration and faster drug release can be achieved by the buccal film of Silodosin.
No takes yet. Share an insight, caveat, or question.
Bhargavi Patel1*, Bhakti Shah2, Dr. Shailesh T. Prajapati 3 (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: